U.S. Markets close in 5 hrs 35 mins
  • S&P 500

    4,267.54
    -12.61 (-0.29%)
     
  • Dow 30

    33,722.40
    -38.65 (-0.11%)
     
  • Nasdaq

    13,007.74
    -39.44 (-0.30%)
     
  • Russell 2000

    2,001.37
    -15.25 (-0.76%)
     
  • Crude Oil

    87.82
    -4.27 (-4.64%)
     
  • Gold

    1,792.10
    -23.40 (-1.29%)
     
  • Silver

    20.09
    -0.60 (-2.91%)
     
  • EUR/USD

    1.0194
    -0.0064 (-0.6218%)
     
  • 10-Yr Bond

    2.7730
    -0.0760 (-2.67%)
     
  • Vix

    20.48
    +0.95 (+4.86%)
     
  • GBP/USD

    1.2081
    -0.0057 (-0.4724%)
     
  • USD/JPY

    132.9410
    -0.5390 (-0.4038%)
     
  • BTC-USD

    24,126.08
    -397.38 (-1.62%)
     
  • CMC Crypto 200

    573.25
    -17.51 (-2.96%)
     
  • FTSE 100

    7,494.04
    -6.85 (-0.09%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

Woman-Health Focused Stock Agile Therapeutics Is 'Better Positioned,' Analyst Says While Upgrading Stock

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Maxim Group upgraded Agile Therapeutics Inc (NASDAQ: AGRX) to Buy from Hold with a price target of $1, saying it should be better positioned to begin to rebound.

  • Agile recently closed an equity offering, raising around $24 million in gross proceeds, and brought in around $12.8 million from its ATM facility. The cash runway should be sufficient into 1Q23.

  • In addition, management is enacting austerity measures and refining its commercial efforts, Maxim notes.

  • Related: HC Wainwright Sees Agile Therapeutics' Twirla Tailwinds Post Roe-Wade Ruling.

  • Additionally, Maxim believes that Agile now has some 'breathing room' to focus on its commercial strategy for Twirla.

  • Several potential tailwinds in the women's health space could benefit Twirla's trajectory.

  • These include the Wade vs. Roe decision in June, which in part has brought increased focus on contraceptive options and access for women to the forefront.

  • Related: Agile Therapeutics Tightens Q2 Forecast For Contraceptive Patch 'Twirla.'

  • According to Maxim, Agile's Twirla remains the safest contraceptive patch option as a low-dose estrogen patch, unlike marketed competitors. The combined hormonal contraceptive market is significant, estimated to be ~$4.1B, but most of the market remains focused on pills and rings.

  • Price Action: AGRX shares are up 4.25% at $0.52 during the market session on the last check Tuesday.

Latest Ratings for AGRX

Date

Firm

Action

From

To

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Sep 2021

HC Wainwright & Co.

Maintains

Buy

Jul 2021

RBC Capital

Maintains

Outperform

View More Analyst Ratings for AGRX

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.